Literature DB >> 2063658

MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis.

J L Frederiksen1, H B Larsson, J Olesen, B Stigsby.   

Abstract

A cohort of 50 consecutive patients with acute monosymptomatic optic neuritis (ON) from a defined catchment area joined a prospective study. The aim of this study was to compare the sensitivity of magnetic resonance imaging (MRI), electrophysiological methods (VEP and SEP) and biothesiometry to detect abnormalities in other parts of the CNS than the optic nerves during the acute phase of ON. For each method, a scoring system is proposed. This investigation also hoped to achieve a better understanding of the natural history of ON. MRI proved to be the most sensitive tool (63% abnormal) in confirming a second site of involvement, followed by VEP in the clinically unaffected fellow eye (42%), biothesiometry (32%) and SEP (17%). The combination of all these methods, except for MRI (and VEP in eyes with acute ON), revealed abnormalities in 63% of the patients. When the neurophysiological methods were combined with MRI, 79% of the patients had abnormal findings suggesting additional lesions in the CNS. Hence, MRI and neurophysiological examinations supplement each other and together provide evidence that monosymptomatic ON is usually a first manifestation of MS. The development of definite MS at 1-20 months of follow up in 7 patients (all with abnormal MRI initially) supports this view.

Entities:  

Mesh:

Year:  1991        PMID: 2063658     DOI: 10.1111/j.1600-0404.1991.tb04713.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

1.  Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI.

Authors:  A Ghezzi; V Torri; M Zaffaroni
Journal:  Ital J Neurol Sci       Date:  1996-10

Review 2.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation.

Authors:  G Iannucci; C Tortorella; M Rovaris; M P Sormani; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

4.  Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination.

Authors:  J I O'Riordan; N A Losseff; C Phatouros; A J Thompson; I F Moseley; D G MacManus; W I McDonald; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

5.  Disease-modifying Therapies for Multiple Sclerosis.

Authors:  John R. Corboy; Douglas S. Goodin; Elliot M. Frohman
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

6.  Visual Evoked Potential and Magnetic Resonance Imaging are More Effective Markers of Multiple Sclerosis Progression than Laser Polarimetry with Variable Corneal Compensation.

Authors:  Ema Kantorová; Peter Ziak; Egon Kurča; Mária Koyšová; Mária Hladká; Kamil Zeleňák; Jozef Michalik
Journal:  Front Hum Neurosci       Date:  2014-01-22       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.